Immediate batch documentation, traceable analytical validation, and commercial multi-kilogram supply from our Hangzhou synthesis park.
AOD 9604 (Advanced Obesity Drug 9604, CAS No. 221231-10-3 / 300715-38-7) represents one of the most chemically sophisticated therapeutic peptides derived from human Growth Hormone (hGH). Structurally engineered as a 16-amino-acid synthetic peptide comprising the terminal lipolytic domain of somatotropin (hGH 176–191) with an N-terminal tyrosine substitution, AOD 9604 preserves the primary fat-mobilizing and chondrogenic cascade of native hGH while entirely abolishing affinity for the systemic hGH receptor responsible for diabetogenic side effects, insulin resistance, and IGF-1 elevation.
| Analytical Parameter | Technical Specification | Analytical Methodology | Regulatory Relevance |
|---|---|---|---|
| Primary Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe | Mass Spectrometry (MS/MS) & Edman Sequencing | Sequence Identity Confirmation |
| Disulfide Connectivity | Intramolecular loop between Cys7 and Cys14 | Peptide Mapping via Enzymatic Digestion & UHPLC | Ensures Functional Tertiary Folding |
| Molecular Formula / Weight | C78H123N23O23S2 / 1815.12 Da (monoisotopic: 1813.86 Da) | High-Resolution Orbitrap LC-HRMS | Mass Accuracy < 2 ppm |
| Chemical Purity | ≥ 98.0% (Standard Grade) / ≥ 99.0% (Injectable cGMP Grade) | RP-HPLC (C18 / C8 reverse phase gradients) | Limits Truncated & Deletion Byproducts |
| Counter-Ion Distribution | Acetate (≤ 12.0% w/w) or TFA Controlled (≤ 0.5% w/w) | Ion Chromatography (IC) with Suppressed Conductivity | Physiological Compatibility |
| Bacterial Endotoxin | < 5.0 EU/mg (Bulk Drug) / < 0.5 EU/mg (Ultra-Purified) | Kinetic Turbidimetric Limulus Amebocyte Lysate (LAL) | Parenteral Formulation Safety |
Navigating market expansion, clinical crossover, and dual commercial pipelines across international biotechnology corridors.
While second-generation GLP-1/GIP co-agonists dominate satiety pathways, systemic appetite reduction frequently induces substantial lean muscle mass catabolism. In response, global pharmaceutical sponsors and compounding clinical networks are formulating dual-action protocols combining GLP-1 therapies with AOD 9604 to accelerate visceral adipocyte lipolysis while preserving skeletal muscle proteome integrity.
Beyond adipose regulation, peer-reviewed clinical investigations demonstrate that AOD 9604 promotes chondrocyte proliferation, up-regulates type II collagen deposition, and accelerates proteoglycan biosynthesis in damaged articular cartilage. Global sports medicine consortia and orthopedic CDMOs actively utilize intra-articular formulations to arrest early-stage osteoarthritis without the necrosis risks linked to corticosteroids.
The convergence of non-invasive aesthetic dermatology and peptide science has unlocked substantial demand for topical lipid-clearing cosmeceutical formulations. Thinheal supplies modified palmitoylated, liposomal-encapsulated, and acetate-purified AOD 9604 intermediates to premium skincare manufacturers in Europe, North America, and East Asia seeking validated body-contouring raw ingredients.
The manufacturing complexity of AOD 9604 is fundamentally dictated by its hydrophobic sequence core (Leu-Arg-Ile-Val-Gln) and the requirement for an authentic intramolecular disulfide bond linking Cys7 and Cys14. Traditional liquid-phase peptide synthesis (LPPS) suffers from severe steric hindrance, beta-sheet self-aggregation, and multi-step yield attrition. Thinheal utilizes a fully automated, microwave-assisted orthogonal Solid-Phase Peptide Synthesis (Fmoc-SPPS) paradigm combined with selective high-dilution directed cyclization.
2-Chlorotrityl chloride resin pre-loaded with Fmoc-Phe-OH suppresses C-terminal epimerization and diketopiperazine formation.
Automated addition utilizing Oxyma Pure / DIC coupling reagents, minimizing racemization of prone Arg and Cys residues.
Mild acidolytic cleavage cocktail protects sensitive side-chains while maintaining linear peptide solubility for downstream workup.
Controlled air oxidation / DMSO-mediated cyclization at ppm-level concentrations completely eliminates inter-chain polymer dimers.
Dynamic Axial Compression columns (200mm-450mm ID) purify the monomer, yielding >99.0% optical and diastereomeric purity.
During the disulfide bridging of Cys7 and Cys14, unoptimized high-concentration conditions inevitably trigger inter-chain disulfide bridges, producing toxic polymer multimers. Thinheal's proprietary diluted continuous-flow oxidative reactor achieves a >96% cyclization conversion rate within minutes, virtually eliminating high-molecular-weight protein impurities.
Standard peptide deprotection leaves trifluoroacetate (TFA) salt residues, which cause cytotoxicity in primary chondrocytes and metabolic formulations. Our multi-stage ion-exchange chromatographic systems substitute TFA with pharmaceutical-grade acetic acid, guaranteeing residual TFA levels below 0.1% while maintaining solubility and stability.
Peptide shelf-life is deeply influenced by moisture content and crystal morphology. Utilizing industrial Class A cleanroom freeze-dryers, our cycle control preserves an amorphous cake structure with residual water content controlled strictly below 5.0%, permitting ambient temperature logistics without risk of thermal deamidation.
Combining nearly 20 years of technical management with multi-ton industrial scale, full backward integration, and streamlined regulatory execution.
Our Hangzhou base sources upstream Fmoc-protected amino acids, coupling agents (DIC, HBTU, Oxyma), and specialized resins directly from partnered primary chemical manufacturing bases in Zhejiang and Jiangsu, shielding global clients from global supply shocks.
Equipped with 500L, 1000L, and 3000L glass-lined solid-phase reaction vessels and large-bore preparative HPLC arrays, Thinheal processes multi-ton annual campaigns for blockbuster peptide APIs with lead times measured in days, not quarters.
Our centralized QA/QC laboratory features Bruker 400MHz/600MHz NMR, Agilent 1290 UHPLC-MS/MS, Dionex ICS-6000 ion chromatographs, and automated bioburden workstations, issuing authoritative Certificates of Analysis (CoA) for every single batch.
We maintain active regional export desks serving the USA & Europe, Russia & CIS, Asia-Pacific, and the Middle East, ensuring prompt technical consultations, temperature-controlled cold-chain routing, and customs documentation assistance.
Procuring raw peptide active pharmaceutical ingredients on the global B2B market requires comprehensive due diligence beyond gross catalog pricing. Low initial offers frequently mask sub-potent material containing truncated peptides (such as Des-Phe16 or Des-Tyr1 deletion sequences), excessive TFA counter-ion percentages, or high endotoxin burdens that ruin end-product stability and invalidate regulatory applications.
A Certificate of Analysis reporting 99.0% HPLC purity reflects only the relative peak area of the main chromophore. Sourcing managers must review Net Peptide Content (NPC), which typically ranges from 75% to 88% due to bound counter-ions (acetate/TFA) and residual crystal water. Accurate dosage calculation requires formula reconciliation based on validated Nitrogen content (Kjeldahl/combustion method).
During solid-phase activation of cysteine and histidine residues, optical inversion generates D-amino acid diastereomers (e.g., [D-Cys7]-AOD 9604) that co-elute closely with the target monomer. Thinheal establishes strict baseline chromatographic resolution criteria with chiral HPLC or enzymatic digest mapping to ensure diastereomeric impurities do not exceed 0.5%.
For injectable formulation, reconstitution into sterile diluents requires bulk API endotoxin levels well beneath USP <85> thresholds. Thinheal performs rigorous depyrogenation on all lyophilization equipment, packaging vials, and synthesis reagents, guaranteeing bulk shipments reach < 0.1 EU/mg upon customer receipt.
When submitting your RFQ to our Hangzhou technical team, please specify: (1) Target Purity Tier (≥98% research grade vs. ≥99% pharma cGMP grade), (2) Counter-ion Preference (Lyophilized Acetate Salt vs. Controlled TFA), (3) Packaging Presentation (Custom aliquots in 5mg/10mg sterile vials vs. 100g/500g/1kg bulk poly-sealed fluoropolymer canisters), and (4) Regulatory Support Documents needed (DMF type II filings, stability matrices, or vendor audit questionnaires).
Tailored synthesis specifications engineered for specific drug delivery formats and consumer healthcare categories.
Engineered with neutral pH isotonic stabilizers, requiring ultra-low endotoxin (<0.05 EU/mg) and acetate-salt purity >99.0% to prevent injection-site irritation and guarantee 24-month refrigerated reconstituted stability.
Optimized for co-formulation with high-molecular-weight sodium hyaluronate. High net peptide content ensures reliable micro-dosing directly into synovial cavities for cartilage preservation protocols.
Manufactured with lipophilic fatty acid conjugation or micro-encapsulation compatibility for premium aesthetic clinic treatments targeting localized subcutaneous adipose deposits.
Packaged in vacuum-sealed borosilicate glass Type I vials with pharmaceutical-grade chlorobutyl rubber stoppers, preventing oxidation of Cys and Tyr residues under ambient logistics.
Direct answers to common technical, quality control, and international shipping inquiries.
Explore our verified solid-phase synthetic portfolio available for contract research and commercial manufacturing.
Whether your program demands analytical evaluation samples, salt-exchanged bulk APIs, or complete technical dossier transfer, our Hangzhou CDMO specialists respond with comprehensive technical data within 12 hours.
Thin